Former FDA Commissioner Scott Gottlieb said the United States should be stockpiling supplies of therapeutic antibodies even before any approval or authorization of emergency use to treat COVID-19.
“We need a more coordinated national strategy around this,” he said on CBS ‘”Face the Nation” today.
The government should be working with companies before actual approval to ensure sufficient supplies are available, he said. “We lost the window to do it in remdesivir,” he said, speaking about the Gilead Science drug that received emergency use authorization in May.
Companies developing antibody treatments for the blood of patients with COVID-19 include Eli Lilly (NYSE: LLY), Regeneron (NASDAQ: REGN), AbCellera Biologics, AstraZeneca (NYSE: AZN) and Vir Biotechnology (NASDAQ: VIR ). .
The United States yesterday had about 45.3K new cases of COVID-19, bringing the cumulative number of confirmed cases in the country to 2.85M, according to the Johns Hopkins University Coronavirus Resource Center.
Previously: Lilly Launches Antibody Treatment Study for COVID-19 (June 1)
Dear Readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the political discussion separately.
